Healthcare provider profile · identity verified

Kimberly Angenee Smith, MD

Family Practice · BALDWIN PARK, CA · NPI 1811056401

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	293	111
Lisinopril	Lisinopril	263	94
Simvastatin	Simvastatin	257	85
Losartan Potassium	Losartan Potassium	234	84
Amlodipine Besylate	Amlodipine Besylate	226	91
Levothyroxine Sodium	Levothyroxine Sodium	207	65
Albuterol Sulfate Hfa	Albuterol Sulfate	171	76
Metoprolol Tartrate	Metoprolol Tartrate	149	52
Metformin Hcl	Metformin Hcl	147	55
Omeprazole	Omeprazole	142	56
Alendronate Sodium	Alendronate Sodium	124	36
Atenolol	Atenolol	123	39
Hydrochlorothiazide	Hydrochlorothiazide	121	41
Rosuvastatin Calcium	Rosuvastatin Calcium	110	44
Furosemide	Furosemide	104	35
Meloxicam	Meloxicam	104	56
Metformin Hcl Er	Metformin Hcl	92	35
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	90	17
Glipizide	Glipizide	80	30
Ibuprofen	Ibuprofen	73	32
Gabapentin	Gabapentin	70	24
Humulin N	Insulin Nph Human Isophane	70	22
Famotidine	Famotidine	69	29
Potassium Chloride	Potassium Chloride	68	27
Prednisone	Prednisone	58	53
Tramadol Hcl	Tramadol Hcl	58	18
Lorazepam	Lorazepam	54	17
Trazodone Hcl	Trazodone Hcl	54	16
Pantoprazole Sodium	Pantoprazole Sodium	51	19
Sertraline Hcl	Sertraline Hcl	49	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	45	14
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	45	13
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	44	18
Spiriva Respimat	Tiotropium Bromide	43	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	42	suppressed
Azithromycin	Azithromycin	41	36
Triamcinolone Acetonide	Triamcinolone Acetonide	41	32
Wixela Inhub	Fluticasone Propion/Salmeterol	41	16
Spironolactone	Spironolactone	39	14
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	37	13
Buspirone Hcl	Buspirone Hcl	36	17
Cephalexin	Cephalexin	36	34
Fenofibrate	Fenofibrate	34	suppressed
Alvesco	Ciclesonide	33	17
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	31	28
Bisoprolol Fumarate	Bisoprolol Fumarate	31	11
Acyclovir	Acyclovir	30	suppressed
Terazosin Hcl	Terazosin Hcl	30	11
Doxycycline Monohydrate	Doxycycline Monohydrate	29	28
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Lactulose	Lactulose	29	18
Morphine Sulfate Er	Morphine Sulfate	29	suppressed
Allopurinol	Allopurinol	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	27	suppressed
Montelukast Sodium	Montelukast Sodium	26	11
Carvedilol	Carvedilol	25	11
Hydrocortisone	Hydrocortisone	25	16
Fentanyl	Fentanyl	24	suppressed
Ondansetron Hcl	Ondansetron Hcl	24	13
Acetaminophen-Codeine	Acetaminophen With Codeine	23	suppressed
Naproxen	Naproxen	23	13
Ciprofloxacin Hcl	Ciprofloxacin Hcl	22	12
Lidocaine	Lidocaine	22	suppressed
Lovastatin	Lovastatin	22	suppressed
Mirtazapine	Mirtazapine	22	suppressed
Nystatin	Nystatin	22	14
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	21	21
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	20	suppressed
Ondansetron Odt	Ondansetron	20	suppressed
Pravastatin Sodium	Pravastatin Sodium	20	suppressed
Amoxicillin	Amoxicillin	19	14
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	19	suppressed
Duloxetine Hcl	Duloxetine Hcl	18	suppressed
Ibandronate Sodium	Ibandronate Sodium	18	suppressed
Mupirocin	Mupirocin	18	11
Topiramate	Topiramate	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Colchicine	Colchicine	16	suppressed
Humulin R	Insulin Regular, Human	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	15	suppressed
Metronidazole	Metronidazole	15	14
Donepezil Hcl	Donepezil Hcl	14	suppressed
Eliquis	Apixaban	14	suppressed
Estradiol	Estradiol	14	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	14	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	14	suppressed
Lidocaine Hcl Viscous	Lidocaine Hcl	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	14
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	13	13
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Ofloxacin	Ofloxacin	13	12
Ezetimibe	Ezetimibe	12	suppressed
Jardiance	Empagliflozin	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error